liraglutide

12/01/2009 - "Throughout the trials, liraglutide was associated with weight reduction; in most instances, the reduction from baseline was significantly greater than that seen with comparators. "
03/01/2015 - "Treatment with liraglutide in a real-world setting is associated with low therapy failure, good glycemic response, weight loss, and improvement in systolic blood pressure and lipid profile. "
01/01/2015 - "Short-term liraglutide treatment was associated with weight loss and significantly improved eating behavior in obese women with PCOS."
01/01/2012 - "Liraglutide produced meaningful long-term weight loss and significantly improved eating behavior in obese Japanese patients with type 2 diabetes."
01/01/2011 - "In addition liraglutide significantly improved β-cell function, reduced systolic blood pressure (BP) and induced weight loss. "

09/01/2015 - "As appetite suppressions and associated decreases in body weights were not observed in obese patients, the efficacy of liraglutide at 0.9 mg did not appear to be high. "
01/01/2012 - "Clinically significant reduction in body weight, systolic blood pressure and improvement in lipid profile were noticed with liraglutide therapy in addition to glycemic control."
06/01/2015 - "Based on this population pharmacokinetic analysis, the liraglutide dose regimen that was found to be clinically effective in adults is predicted to achieve the same range of exposure in the pediatric population (10-17 years of age) with a pre-trial body weight range of 57-214 kg."
07/02/2015 - "In this study, 3.0 mg of liraglutide, as an adjunct to diet and exercise, was associated with reduced body weight and improved metabolic control. "
10/01/2015 - "Liraglutide monotherapy for 24 weeks improved beta cell responsiveness with no change in either body weight or fat distribution. "

06/01/2014 - "Preliminary studies on IDegLira indicate improved overall glycemic control, better safety profile with reduction in bodyweight and low rate of hypoglycemia compared to IDeg but higher rates of hypoglycemia than liraglutide therapy alone. "
12/01/2013 - "Symptomatic hypoglycemia was reported in only one study with liraglutide in patients without diabetes and was not objectively confirmed by laboratory data. "
11/01/2015 - "The incidence of hypoglycemia episode in the liraglutide group was significantly lower than in the NPH group (p<0.05). "
01/01/2015 - "The risk of hypoglycemia associated with liraglutide treatment is low."
12/01/2014 - "Despite this level of glycemic control, no difference was found in the incidence of hypoglycemia between the liraglutide and placebo groups (P = 0.61). "

04/01/2010 - "The addition of liraglutide to SU treatment for 24 weeks dose-dependently improved glycaemic control vs. SU monotherapy, without causing major hypoglycaemia or weight gain or loss."
09/01/2015 - "Liraglutide prevents fast weight gain and β-cell dysfunction in male catch-up growth rats."
06/01/2014 - "At 12 weeks, more patients in the liraglutide compared with the sulphonylurea group achieved a composite endpoint of haemoglobin A1c (HbA1c) < 7%, no weight gain and no severe hypoglycaemia but this did not reach statistical significance [odds ratio (OR) 4.08, 95% confidence interval (CI) 0.97, 17.22, p = 0.06]. "
03/01/2013 - "Extended dosing periods have demonstrated the durability of response of liraglutide with respect to glycemic control, lack of weight gain, and blood pressure benefits. "
01/01/2012 - "As assessed by the composite outcome of HbA1c <7%, no hypoglycaemia and no weight gain, liraglutide was clearly superior to the other commonly used therapies. "

02/01/2007 - "This article reviews the mechanisms of action and efficacy of liraglutide for the treatment of Type 2 diabetes mellitus. "
11/01/2014 - "Liraglutide has been widely used in the treatment of type 2 diabetes mellitus (T2DM), however, the results of a number of randomized placebo-controlled trials on the effects of liraglutide for the treatment of T2DM have varied. "
11/01/2014 - "Liraglutide for the treatment of type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials."
11/01/2013 - "This study investigated the effects of steady-state liraglutide 1.8 mg versus placebo on postprandial plasma lipid concentrations after 3 weeks of treatment in patients with type 2 diabetes mellitus (T2DM). "
06/01/2011 - "The objective of this study is to assess plasma omentin-1 levels in patients with type 2 diabetes mellitus (T2DM) and matched control subjects and to investigate the effects of liraglutide on plasma omentin-1 levels in patients with T2DM. "